-
Product Insights
Plague – Drugs In Development, 2023
Global Markets Direct’s, ‘Plague - Drugs In Development, 2023’, provides an overview of the Plague pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) - Drugs In Development, 2023’, provides an overview of the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Anthrax – Drugs In Development, 2023
Global Markets Direct’s, ‘Anthrax - Drugs In Development, 2023’, provides an overview of the Anthrax pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Neisseria gonorrhoeae Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Neisseria gonorrhoeae Infections - Drugs In Development, 2023’, provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPL-0401 in Proliferative Diabetic Retinopathy (PDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPL-0401 in Proliferative Diabetic Retinopathy (PDR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPL-0401 in Proliferative Diabetic Retinopathy (PDR) Drug Details: OPL-0401 (SAR-407899) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPL-0401 in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPL-0401 in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPL-0401 in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: OPL-0401 (SAR-407899) is...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberculosis - Drugs In Development, 2023’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...